Process for separating proteins from central nervous system tissue and treating experimentally induced demyelinating diseases

Claim 2

A process for separating components with weight average molecular weights of approximately 2,000 to 4,000 having weak encephalitogenic activity and high protective activity from the crude basic protein derived from defatted myelinated mammalian central nervous system material, which comprises dissolving said mammalian central nervous system material in a solution of about 0.005M to about 0.015M sodium carbonate in about 0.01M to about 0.09M ammonium hydroxide, chromatographing said solution containing mammalian central nervous system material on carboxymethylcellulose having sodium cations, eluting said chromatographed solution with approximately 0.01M to 0.03M of sodium chloride in approximately 0.01M to 0.09M ammonium hydroxide solution, collecting said eluate and recovering said components from said eluate.

Claim 3

A process for separating components having weight average molecular weights of approximately 2,000 to 4,000 and having weak encephalitogenic activity and high protective activity from the recovered components of claim 1 which comprises dissolving said components in approximately 0.005M to 0.02M ammonium chloride in approximately 0.005M to 0.02M ammonium hydroxide solution, chromatographing on carboxymethylcellulose in the ammonium form, eluting said chromatographed solution with approximately 0.005M to 0.02M ammonium chloride in approximately 0.005M to 0.2M ammonium hydroxide, collecting said first eluate, eluting said chromatographed solution with approximately 0.1M to 0.5M ammonium chloride in approximately 0.1M to 0.5M ammonium hydroxide, collecting said second eluate and recovering three chromatographically distinct products from said eluates, all three having weight average molecular weights of 2,000 to 4,000 weak encephalitogenic activity and a high protective activity.

Claim 4

The components obtained from the process of claim 1.

Claim 5

The components obtained from the process of claim 2.

Claim 6

A process for treating mammals to reduce symptoms of experimentally induced demyelinating diseases, which comprises injecting said mammals after onset of the disease with large successive doses of the components of claim 4.

Claim 7

A process for separating components with weight average molecular weights of approximately 8,000 to 10,000 having a high encephalitogenic activity from the crude basic protein derived from defatted mylinated mammalian central nervous system material, which comprises dissolving said mammalian central nervous system material in about 0.05M to about 0.015M sodium carbonate in about 0.01M to about 0.09M ammonium hydroxide solution, chromatographing said solution containing mammalian central nervous system material on carboxymethylcellulose having sodium cations; eluting said chromatographed solution with approximately 0.01M to 0.03M of sodium chloride in approximately 0.01M to 0.09M ammonium hydroxide solution; collecting said first eluate; eluting said chromatographed solution with approximately 0.1M to 0.5M sodium chloride in 0.01M to 0.09M ammonium hydroxide; collecting said second eluate; and recovering said components from said second eluate.

Claim 8

A process for separating components with weight average molecular weights of approximately 8,000 to 10,000 having a high encephalitogenic activity from the crude basic protein derived from defatted mylinated mammalian central nervous system material, which comprises dissolving said mammalian central nervous system material in about 0.05M to about 0.015M sodium carbonate in about 0.01M to about 0.09M ammonium hydroxide solution, chromatographing said solution containing mammalian central nervous system material on carboxymethylcellulose having sodium cations; eluting said chromatographed solution with approximately 0.01M to 0.03M of sodium chloride in approximately 0.01M to 0.09M ammonium hydroxide solution; collecting said first eluate; eluting said chromatographed solution with approximately 0.1M to 0.5M sodium chloride in 0.01M to 0.09M ammonium hydroxide; collecting said second eluate; and recovering said components from said second eluate.

Claim 9

A process for separating components with weight average molecular weights of approximately 2,000 to 4,000 having weak encephalitogenic activity and high protective activity from the recovered components of claim 6 which comprises treating said components with about 5N to 7N hydrochloride acid, recovering the crude material, dissolving said crude material in about 0.005M to about 0.015M sodium carbonate in about 0.01M to about 0.09M ammonium hydroxide solution, chromatographing said solution containing said crude material on carboxymethylcellulose having sodium cations and eluting said chromatographed solution with approximately 0.01M to 0.03M of sodium chloride in approximately 0.01M to 0.09M ammonium hydroxide solution, collecting said eluate and recovering said components therefrom.

Claim 10

A process for separating components having weight average molecular weights of approximately 2,000 to 4,000 and weak encephalitogenic activity and a high protective activity from the recovered components of claim 7 which comprises, dissolving said components in approximately 0.005M to 0.02M ammonium chloride in approximately 0.005M to 0.02M ammonium hydroxide solution, chromatographing on carboxymethylcellulose in the ammonium form, eluting said chromatographed solution with approximately 0.005M to 0.02M ammonium chloride in approximately 0.005M to 0.2M ammonium hydroxide, collecting said first eluate, eluting said chromatographed solution with approximately 0.1M to 0.5M ammonium chloride in approximately 0.1M to 0.5M ammonium hydroxide, collecting said second eluate and recovering four chromatographically distinct products from said eluates, all four having weight average molecular weights of 2,000 to 4,000, weak encephalitogenic activity and a high protective activity.

Claim 11

The components obtained from the process of claim 7.

Claim 12

The components obtained from the process of claim 8.

Claim 13

A process for treating mammals to reduce symptoms of experimentaly induced demyelinating diseases which comprises injecting said mammals after onset of the disease with large successive doses of the components of claim 10.